Abbott Laboratories Corporation

Tap Holdings, LLC

Tap Pharmaceuticals, Inc.

Charles J Nichols

Fortuna Haviv

Nicholas A Mort

Jonathan Greer

Rolf E Swenson

Timothy D Fitzpatrick

John T Randolph

Daryl Richard Sauer

Christopher R Dalton

Wesley J Dwight

Philip Waid

The present invention relates to a class of heptapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.

C-terminus modified heptapeptide LHRH analogs

Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.

Macrolide LHRH antagonists

6-position modified decapeptide LHRH antagonists

Decapaptide and undecapaptides substituted on the N-terminal nitrogen atom by acyl groups which include furo-2-yl, isonicotinyl, nicotinyl, 2-, 3-, and 4-quinolinecarbonyl, shikimyl, dihydroshikimyl, and tetrahydrofur-2-oyl are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.

N-terminus modified analogs of LHRH

Decapaptides substituted on the N-terminal nitrogen atom by acyl groups are potent antagonists of LHRH and are useful for suppressing the levels of sex hormones in mammals.

Growing community of inventors

Greendale, WI, United States of America

Charles J Nichols